In a bold move that’s sparking both praise and debate, Western Australia has become the second state to take matters into its own hands by funding RSV vaccines for older Australians, stepping in where the Federal Government has hesitated. But here’s where it gets controversial: while the Pharmaceutical Benefits Advisory Committee (PBAC) has repeatedly recommended adding these vaccines to the National Immunisation Program (NIP) for those aged 65 and over, the Federal Government has yet to act. With a private prescription costing around $300, many seniors have been left unprotected—until now. The WA Government is set to fund the Arexvy vaccine for approximately 15,000 aged care residents, following Victoria’s lead from last year. This decision comes just in time for the looming flu season, raising questions about why the Federal Government hasn’t prioritized this issue. And this is the part most people miss: the PBAC’s recommendations were based on submissions from pharmaceutical giants GSK and Pfizer over the past 18 months, yet the rollout remains patchy. Is this a triumph of state initiative, or a glaring failure of national healthcare policy? Let’s dive deeper into why this matters—and why it’s dividing opinions. Should states take the lead when federal action stalls, or is this a slippery slope toward inconsistent healthcare access? Share your thoughts below!
